The Matracell process — utilized in cardiovascular and dermal allografts — yields a strong, acellular scaffold that facilitates cell proliferation, cell migration and vascularization. Only tissue processed with Matracell technology meets the threshold of being truly decellularized, minimizing the possibility of an immune response.
Although several dermal products claim to be “decellularized”, not all decellularization processes meet the definition developed by Crapo, Gilbert, and Badylak.* After evaluating remodeling responses and adverse cell and host responses, the authors determined that an ADM needs to contain less than 50ng dsDNA/mg to satisfy the intent of decellularization. Only Matracell‑treated tissue meets that criteria.
- Peer Reviewed Articles
*An overview of tissue and whole organ decellularization processes. Biomaterials. 2011.
Crapo PM, Gilbert TW & Badylak SF. An overview of tissue and whole organ decellularization processes. Biomaterials. 2011. April;32(12):3233-3243Biological incorporation of human acellular dermal matrix used in Achilles tendon repair. Cell Tissue Bank. 2017
- White Papers and Technical Papers